Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MHRA, the most common co-covered peer. Source depth averages 11 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MHRA, the most common co-covered peer. Source depth averages 11 original sources per story, versus 3.6 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 5.8. NICE appears in 1 tracked Healthcare story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NICE. Shared-story counts are live from our verified record — not editorial picks.
Expected Appeal Date
Final appraisal committee meeting to review new evidence and potential Managed Access Agreements.
National Campaign Launch
Bereaved family and patient advocates launch a coordinated media campaign imploring the NHS to reconsider.
NICE Initial Review
NICE issues a preliminary recommendation against routine funding based on cost-effectiveness.
MHRA Approval
The drug receives safety and efficacy licensing for use in the UK market.
A bereaved family's national campaign has ignited a fierce debate over the NHS's refusal to fund a new treatment for aggressive cancer despite evidence of significant tumor shrinkage. The case underscores the growing tension between rapid pharmaceutical innovation and the UK's rigid cost-effectiveness appraisal frameworks.
NICE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
